Cantuzumab

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.[1]

It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates :

huC242 targets CanAg

"HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1). CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers. It is also expressed in a substantial proportion of gastric cancers (55%), uterine cancers (45%), non-small cell lung cancers (40%), and bladder cancers (40%)."[2]

References

  1. ↑ Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Rodon et al. 2008
  2. ↑ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
This article is issued from Wikipedia - version of the Wednesday, August 26, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.